Key insights from lung cancer research at ASCO 2025
Dr Enriqueta Felip talks to ecancer about the topics that were under discussion at the WCLC 2022 presidential symposium.
Dr Felip says that there was an analysis on screening and tobacco cessation which is really important since tobacco usage causes 85% of lung cancers.
At the symposium other topics under discussion were; better screening technologies especially for smokers, and less aggressive neoadjuvant and surgical techniques. Blood analysis and circulating tumour cells were also discussed.
Even perhaps to discuss the Presidential Symposium, we have started with one analysis of screening and also tobacco cessation is really important. This message is important, that tobacco is the reason for 85% of lung cancer, so it’s important to stop. Screening, we need to work also in screening technologies even in a smoker population. Also we have discussed these studies with neoadjuvant immunotherapy, with adjuvant strategies and also with surgical techniques probably less aggressive.
So this is what we have discussed in the Presidential but also the future of early stage disease would be the analysis of circulating tumour DNA. Blood analysis determinations with technologies, with new technologies, in order to detect the minimal residual disease in the group of patients and, again, trying to treat those patients with high risk of relapse.
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Relapsed refractory multiple myeloma
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC